Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure.

Literature DB >> 2162294

Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure.

Abstract

Enalapril is an effective angiotensin-converting enzyme (ACE) inhibitor which produces salutary, beneficial haemodynamic effects in patients with congestive heart failure. Enalapril also produces beneficial neurohumoral changes, as well as improving abnormal coronary haemodynamics and myocardial energetics that are frequently encountered in these patients. Administration of enalapril once or twice daily appears to be quite effective during maintenance therapy in patients with chronic congestive heart failure.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1990 PMID： 2162294 DOI： 10.2165/00003495-199000394-00007

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

33 in total

1. A comparison of the activity of the angiotensin converting enzyme inhibitors SQ 14 225, SA 446, and MK 421.

Authors: Y Takata; R Di Nicolantonio; F A Mendelsohn; J S Hutchinson; A E Doyle
Journal: Clin Exp Pharmacol Physiol Date: 1983 Mar-Apr Impact factor: 2.557

2. Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure.

Authors: T De Marco; P A Daly; M Liu; S Kayser; W W Parmley; K Chatterjee
Journal: J Am Coll Cardiol Date: 1987-05 Impact factor: 24.094

3. Clinical and hemodynamic experience with enalapril in congestive heart failure.

Authors: R J Cody
Journal: Am J Cardiol Date: 1985-01-11 Impact factor: 2.778

4. Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril).

Authors: F M Fouad; R C Tarazi; E L Bravo; S C Textor
Journal: Hypertension Date: 1984 Mar-Apr Impact factor: 10.190

5. Enalapril maleate and a lysine analogue (MK-521): disposition in man.

Authors: E H Ulm; M Hichens; H J Gomez; A E Till; E Hand; T C Vassil; J Biollaz; H R Brunner; J L Schelling
Journal: Br J Clin Pharmacol Date: 1982-09 Impact factor: 4.335

6. Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension.

Authors: C I Johnston; B J Jackson; I Larmour; R Cubella; D Casley
Journal: Br J Clin Pharmacol Date: 1984 Impact factor: 4.335

7. Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats.

Authors: C S Sweet; P T Arbegast; S L Gaul; E H Blaine; D M Gross
Journal: Eur J Pharmacol Date: 1981-12-03 Impact factor: 4.432

8. Effect of enalapril on renin, angiotensin converting enzyme activity, aldosterone and prostaglandins in patients with hypertension.

Authors: P Larochelle; J Gutkowska; E Schiffrin; O Kuchel; P Hamet; J Genest
Journal: Clin Invest Med Date: 1985 Impact factor: 0.825

9. The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects.

Authors: J F Giudicelli; A Berdeaux; A Edouard; C Richer; D Jacolot
Journal: Br J Clin Pharmacol Date: 1985-09 Impact factor: 4.335

10. Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension--before and after treatment with enalapril (MK 421).

Authors: C E Odya; F P Wilgis; J F Walker; S Oparil
Journal: J Lab Clin Med Date: 1983-11

3 in total